Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

This trial is testing a combination of immunotherapy (serplulimab, a PD-1 blocker) with chemotherapy and radiation therapy as a first-line treatment for people with advanced (metastatic) colorectal cancer, targeting specific tumor types based on their genetic profile. **You may be eligible if...** - You are 18 or older with confirmed Stage IV colorectal cancer - You have not yet received treatment for your metastatic cancer - Your cancer is in the left side of the colon or rectum and is RAS/BRAF wild-type (no mutations), OR it is in the right side/ascending colon with RAS mutations - You have at least one measurable tumor on imaging - You are in good general health (ECOG 0–1) with a life expectancy of at least 3 months - Your blood counts, liver, kidney, and thyroid function are within acceptable ranges **You may NOT be eligible if...** - You have a different type of colon tumor (e.g., gastrointestinal stromal tumor) - Your metastases are surgically removable and you want surgery - You have previously received systemic cancer treatment - You have active autoimmune disease or are on immunosuppressant medications Talk to your doctor to see if this trial is right for you.